Choosing neurodevelopmental and neuronal antibodies: what an otx2 antibody, an nkx2.2 antibody and an mecp2 antibody demand as nuclear targets, what a tyrosine hydroxylase antibody, a synapsin antibody and a uchl1 antibody report in mature tissue, and the stage-matched controls each needs
Developmental markers are stage specific, which makes the control harder than the stain: a negative result can mean the protein is absent, or that the tissue is at the wrong stage, or that the retrieval was wrong. This page covers the nuclear factors and the mature neuronal markers used beside them, and the controls that distinguish those three explanations.
- what a developmental positive control has to be
- stage-matched
- how a synaptic marker is counted, rather than as intensity
- puncta
- the containment human nervous tissue is handled at
- BSL-2
Figures in this panel are the validation and labelling rules a research antibody is bought and used under, named from the guidance itself and linked in the sources below. They are identifiers, not prices: BioBricks publishes verified prices for synthesis services only, and does not imply a reagent price index it has not measured.
- 4 vendor service pages verifiedevery figure matched verbatim to the vendor's page
- Quoted and dated, never estimatedlast verification pass 2026-08-24
- 1 service classes coveredeach with measured search demand behind it
Staining a developing or mature nervous system
- Use a stage-matched positive control, not just a positive tissue. These factors are expressed in defined regions at defined stages. A positive control from the wrong stage is not a control, and it is the commonest reason a developmental stain is reported as failed when the protocol was fine.
- Treat nuclear factors as low abundance nuclear targets. They need a retrieval and a permeabilisation matched to the nucleus, and frequently an amplified detection. A protocol that works for a cytoskeletal or synaptic marker will report absence for these.
- Read a synaptic marker as puncta. Presynaptic markers concentrate at terminals, so the readout is puncta number and density along a process rather than total intensity. Total intensity conflates more synapses with more protein per synapse.
- Know what a neuronal cytoplasmic marker does and does not count. A pan-neuronal cytoplasmic marker fills the cell and is excellent for morphology and for confirming neuronal identity, and it is a poor basis for counting because processes overlap. Count on a nuclear marker and describe with a cytoplasmic one.
- Fix the fixation and record the interval. Several of these epitopes degrade with time to fixation and behave differently in over-fixed archival blocks. Record fixation time and post-mortem interval with every sample; a cohort inconsistent in these cannot be compared.
Multiplexing across compartments
Combining a nuclear factor, a cytoplasmic neuronal marker and a synaptic marker on one section is straightforward if the primaries come from different hosts, and the compartments themselves help separate the channels visually.
Nervous tissue autofluoresces strongly in the green from lipofuscin and fixation, so put the dimmest marker at a longer wavelength and image an unstained section at the experiment's settings first.
Model systems and their own controls
Organoids and differentiated cultures express these markers on their own schedule, which rarely matches the tissue timetable. Establish the expected pattern in your own system before interpreting a difference between conditions.
Where a differentiation protocol is being assessed, a marker panel read at several time points is far more informative than an endpoint, because the interesting failures are usually in the timing rather than the endpoint.
Common questions
- Why is my developmental marker negative?
- It may be the wrong stage rather than a failed stain. These factors are expressed in defined regions at defined times, so a stage-matched positive control is what separates absent protein from a protocol problem.
- What retrieval do nuclear developmental factors need?
- Heat induced retrieval, tested at both a citrate buffer near pH six and a Tris buffer near pH nine on a known positive. The right condition differs between these targets and cannot be assumed from a related one.
- How should a synaptic marker be quantified?
- As puncta density along a defined length of process or within a defined region, with fixed acquisition settings. Total intensity cannot separate more synapses from more protein per synapse.
- Can I count neurons with a cytoplasmic pan-neuronal marker?
- Poorly, because processes overlap and cell boundaries are unclear. Count on a nuclear neuronal marker and use the cytoplasmic one to describe morphology and confirm identity.
Get a shortlist for your project
Browse by service class
Sources
Cite or embed this figure
The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.
Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/neurodevelopmental-antibodies/.